PROPANC BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent
PROPANC BIOPHARMA, INC. (PPCB) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent of 2.22% for the 12-month period ending 2015-06-30, per its 10-K filed 2015-09-30.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense · last filed 2015-09-30
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, noncontrolling interest income (loss), percent for fiscal 2015 was 2.22%, a 59.64% decline from fiscal 2014.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, noncontrolling interest income (loss), percent for fiscal 2014 was 5.50%, a 36.82% increase from fiscal 2013.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, noncontrolling interest income (loss), percent for fiscal 2013 was 4.02%.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent 12 month |
|---|---|
| 2015-06-30 | 2.22% 10-K · filed 2015-09-30 |
| 2014-06-30 | 5.50% 10-K · filed 2015-09-30 |
| 2013-06-30 | 4.02% 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |